1-phenethyl-2-phenylbenzo[d]imidazole | 95866-89-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-phenethyl-2-phenylbenzo[d]imidazole
• 英文别名: 1-phenethyl-2-phenyl-1H-benzo[d]imidazole；1-Phenethyl-2-phenyl-benzimidazol；1-phenethyl-2-phenyl-1H-benzoimidazole；2-Phenyl-1-(2-phenylethyl)benzimidazole
• CAS: 95866-89-0
• 化学式: C₂₁H₁₈N₂
• 分子量: 298.387
• InChiKey: YDVQIPRITAUFQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-(2-phenylethyl)-2-aminoaniline 、 苄胺 在 Al cations incorporated into the Si framework 、 open air 作用下， 以 neat (no solvent) 为溶剂， 反应 15.0h， 以78%的产率得到1-phenethyl-2-phenylbenzo[d]imidazole
  参考文献：
  名称：

  使用 Al-MCM-41 催化剂从伯胺轻松生产苯并咪唑和喹喔啉的多相催化策略

  摘要：

  该研究报告了一种直接的多相催化 (Al-MCM-41) 方法，可在无溶剂条件下从伯胺合成氮杂环部分。Al-MCM-41 催化剂是使用水热法制备的，并通过各种分析技术进行表征。催化方法的可能性和局限性以各种底物呈现。催化方法为各种苯并咪唑和喹喔啉部分提供了一条有吸引力的路线，产率从好到极好。Al-MCM-41 催化剂的克级反应和可重复使用性（最多五个循环）将极大地有益于工业应用。

  DOI：

  10.1039/d1gc02627e

文献信息

• Compounds that enhance Atoh-1 expression
  申请人：MASSACHUSETTS EYE & EAR INFIRMARY

  公开号：EP2732819A2

  公开（公告）日：2014-05-21

  This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g. a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.

  本发明一般提供化合物、药物组合物及其使用方法，其中包括导致生物细胞中 Atoh1 基因（如 Hath1）表达增加的方法。更具体地说，本发明涉及可从 Atoh1 表达增加中获益的疾病和/或失调症的治疗，例如与听觉毛细胞丧失有关的听力损伤或失调症，或与细胞异常增殖有关的失调症。
• COMPOUNDS THAT ENHANCE ATOH-1 EXPRESSION
  申请人：Massachusetts Eye & Ear Infirmary

  公开号：EP2254572B1

  公开（公告）日：2013-10-16
• Compounds that Enhance Atoh1 Expression
  申请人：Massachusetts Eye & Ear Infirmary

  公开号：US20150157607A1

  公开（公告）日：2015-06-11

  This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
• Compounds That Enhance ATOH1 Expression
  申请人：Massachusetts Eye & Ear Infirmary

  公开号：US20170095481A1

  公开（公告）日：2017-04-06

  This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.
• US8859597B2
  申请人：——

  公开号：US8859597B2

  公开（公告）日：2014-10-14